9-Deazaguanine (Synonyms: NSC 344522) |
Katalog-Nr.GC42644
One-Click Copy Product Info
|
9-Deazaguanine is a purine nucleoside analog with oral activity, functioning as a potent inhibitor of purine nucleoside phosphorylase (PNP).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 65996-58-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
9-Deazaguanine is a purine nucleoside analog with oral activity, functioning as a potent inhibitor of purine nucleoside phosphorylase (PNP)[1-2]. 9-Deazaguanine inhibits DNA and RNA replication by competitively inhibiting the incorporation of guanine into nucleic acid structures and interfering with the binding of guanine to proteins[3-4].
In vitro, 9-Deazaguanine and difluoromethylene phosphonic acid analogs (DFPP-DG, 9-13) (0.1–100μM) were used to treat human lymphocytes, B-cell and T-cell leukemia, and lymphoma cell lines for 72 hours. 9-Deazaguanine showed mild inhibitory activity on cell proliferation[5].
In vivo, 9-Deazaguanine (67µmoles/kg) was administered as a single intravenous injection to anesthetized Sprague-Dawley rats. 9-Deazaguanine significantly increased urine volume, sodium excretion, and glucose excretion in the rats[6].
References:
[1] Wielgus-Kutrowska B, Breer K, Hashimoto M, et al. Trimeric purine nucleoside phosphorylase: exploring postulated one-third-of-the-sites binding in the transition state. Bioorg Med Chem. 2012 Nov 15;20(22):6758-69.
[2] V T Minnow Y, Suthagar K, Clinch K, et al. Inhibition and Mechanism of Plasmodium falciparum Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase. ACS Chem Biol. 2022 Dec 16;17(12):3407-3419.
[3] Abu El Asrar R, Margamuljana L, Abramov M, et al. Enzymatic Incorporation of Modified Purine Nucleotides in DNA. Chembiochem. 2017 Dec 14;18(24):2408-2415.
[4] Tian G, Katchur SR, Jiang Y, et al. Small molecule-mediated allosteric activation of the base excision repair enzyme 8-oxoguanine DNA glycosylase and its impact on mitochondrial function. Sci Rep. 2022 Aug 29;12(1):14685.
[5] Glavas-Obrovac L, Suver M, Hikishima S, et al. Antiproliferative activity of purine nucleoside phosphorylase multisubstrate analogue inhibitors containing difluoromethylene phosphonic acid against leukaemia and lymphoma cells. Chem Biol Drug Des. 2010 Apr;75(4):392-9.
[6] Jackson EK, Mi Z, Kleyman TR, et al. 8-Aminoguanine Induces Diuresis, Natriuresis, and Glucosuria by Inhibiting Purine Nucleoside Phosphorylase and Reduces Potassium Excretion by Inhibiting Rac1. J Am Heart Assoc. 2018 Nov 6;7(21):e010085.
| Cell experiment [1]: | |
Cell lines | Human lymphocytes (Ly), chronic myeloid leukaemia in blasts crisis (K562), T-cell leukaemia (JURKAT and MOLT), T-cell lymphoma (HuT78), Burkett's lymphoma (RAJI), acute T-cell lymphoblastic leukaemia (CCRF-CEM), and acute myeloid leukaemia (HL-60) |
Preparation Method | Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified 5% CO₂ incubator. Exponentially growing cells were treated with 9-Deazaguanine (0.1–100μM) and its difluoromethylene phosphonic acid analogues (compounds 9-13) for 72 hours. |
Reaction Conditions | 0.1–100μM; 72h |
Applications | 9-Deazaguanine had no significant influence on lymphocyte or tumour cell growth compared to untreated controls. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Rats were anesthetized with Inactin (90mg/kg; i.p.) and surgically instrumented for hemodynamic monitoring and urine collection. After a stabilization period, a single intravenous bolus of 9-Deazaguanine (67µmoles/kg) was administered. Urine was collected during specific periods before and after administration for analysis of volume and solute excretion. |
Dosage form | 67µmoles/kg; i.v.; Single bolus. |
Applications | 9-Deazaguanine administration led to significant increases in urine volume, sodium excretion (natriuresis), and glucose excretion (glucosuria). However, unlike 8-Aminoguanine, 9-Deazaguanine did not significantly reduce potassium excretion. The diuretic, natriuretic, and glucosuric effects of 9-Deazaguanine were similar to those induced by the purine nucleoside phosphorylase (PNPase) inhibitor 8-Aminoguanine, indicating that its renal effects are mediated through the inhibition of PNPase. |
References: | |
| Cas No. | 65996-58-9 | SDF | |
| Überlieferungen | NSC 344522 | ||
| Canonical SMILES | NC(N1)=NC2=C(NC=C2)C1=O | ||
| Formula | C6H6N4O | M.Wt | 150.1 |
| Löslichkeit | DMF: 2.5 mg/ml,DMSO: 20 mg/ml,DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml,Ethanol: slightly soluble,PBS (pH 7.2): slightly soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.6622 mL | 33.3111 mL | 66.6223 mL |
| 5 mM | 1.3324 mL | 6.6622 mL | 13.3245 mL |
| 10 mM | 666.2 μL | 3.3311 mL | 6.6622 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)